FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

David Stern

Research Profile

Phenomena

Phosphorylation

Chemicals & Drugs

Physiology

Disorders

Co-author Network

Publications

TOP 3
Matthew A Held; Andrew Koo; Casey G Langdon; Zongzhi Liu; James T Platt; Antonella Bacchiocchi; Marcus W Bosenberg; Ashok Chakraborty; Tisheeka Graham-Steed; Jonathan W Haskins; David F Stern
Genotype-selective combination therapies for melanoma identified by high-throughput drug screening.
Michael Krauthammer; Richard P Lifton; Roger S Lo; Shuangge Ma; Shrikant M Mane; Miguel A Materin; James P McCusker; Deepak Narayan; Joseph Schlessinger; David F Stern; Mario Sznol; Stephan Ariyan; Antonella Bacchiocchi; Titus J Boggon; Marcus W Bosenberg; Douglas E Brash; Ana Capatana; Elaine Cheng; Murim Choi; Matthew J Davis; Ken Dutton-Regester; Perry Evans; Gerald Goh; Byung Hak Ha; Nicholas K Hayward; Edna C Holman; Kenneth K Kidd; Harriet M Kluger; Yong Kong; Ruth Halaban
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.
Jinping Liu; Shukun Luo; David F Stern; Bo Xu; Xingzhi Xu; Chunying Yang; Jing Li; Ji Liao; Hongchang Zhao; Keqiong Ye
Structural mechanism of the phosphorylation-dependent dimerization of the MDC1 forkhead-associated domain.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of David Stern (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Matthew A Held; Andrew Koo; Casey G Langdon; Zongzhi Liu; James T Platt; Antonella Bacchiocchi; Marcus W Bosenberg; Ashok Chakraborty; Tisheeka Graham-Steed; Jonathan W Haskins; David F Stern
Genotype-selective combination therapies for melanoma identified by high-throughput drug screening.
Cancer discovery 2013;3(1):52-67.
2012: Michael Krauthammer; Richard P Lifton; Roger S Lo; Shuangge Ma; Shrikant M Mane; Miguel A Materin; James P McCusker; Deepak Narayan; Joseph Schlessinger; David F Stern; Mario Sznol; Stephan Ariyan; Antonella Bacchiocchi; Titus J Boggon; Marcus W Bosenberg; Douglas E Brash; Ana Capatana; Elaine Cheng; Murim Choi; Matthew J Davis; Ken Dutton-Regester; Perry Evans; Gerald Goh; Byung Hak Ha; Nicholas K Hayward; Edna C Holman; Kenneth K Kidd; Harriet M Kluger; Yong Kong; Ruth Halaban
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.
Nature genetics 2012;44(9):1006-14.
2012: Jinping Liu; Shukun Luo; David F Stern; Bo Xu; Xingzhi Xu; Chunying Yang; Jing Li; Ji Liao; Hongchang Zhao; Keqiong Ye
Structural mechanism of the phosphorylation-dependent dimerization of the MDC1 forkhead-associated domain.
Nucleic acids research 2012;40(9):3898-912.
2011: Kathleen A Wilson; David Tuck; Patricia Heffernan Wakefield; Sierra A Colavito; Vincent Schulz; William Sessa; David F Stern
NFBD1/MDC1 regulates Cav1 and Cav2 independently of DNA damage and p53.
Molecular cancer research : MCR 2011;9(6):766-81.
2011: David F Stern
"Competence" progress.
Molecular cell 2011;42(4):411-2.
2011: S E Godshalk; T Paranjape; S Nallur; William C Speed; E Chan; A M Molinaro; A Bacchiocchi; K Hoyt; K Tworkoski; David F Stern; M Sznol; S Ariyan; R Lazova; Ruth Halaban; K K Kidd; Joanne B Weidhaas; Frank J Slack
A Variant in a MicroRNA complementary site in the 3' UTR of the KIT oncogene increases risk of acral melanoma.
Oncogene 2011;30(13):1542-50.
2010: David F Stern
EGFs and ERBBs--brief history and prospects.
Seminars in cell & developmental biology 2010;21(9):917-21.
2010: Maureen Gilmore-Hebert; Rajani Ramabhadran; David F Stern
Interactions of ErbB4 and Kap1 connect the growth factor and DNA damage response pathways.
Molecular cancer research : MCR 2010;8(10):1388-98.
2010: Amnon Golan; Elah Pick; Lyuben Tsvetkov; Yasmine Nadler; Harriet M Kluger; David F Stern
Centrosomal Chk2 in DNA damage responses and cell cycle progression.
Cell cycle (Georgetown, Tex.) 2010;9(13):2647-56.
2010: Janine Mok; Philip M Kim; Hugo Y K Lam; Stacy Piccirillo; Xiuqiong Zhou; Grace R Jeschke; Douglas L Sheridan; Sirlester A Parker; Ved Desai; Miri Jwa; Elisabetta Cameroni; Hengyao Niu; Matthew Good; Attila Remenyi; Jia-Lin Nianhan Ma; YJ Sheu; Holly E Sassi; Richelle Sopko; Clarence S M Chan; Claudio de Virgilio; Nancy M Hollingsworth; Wendell A Lim; David F Stern; Bruce Stillman; Brenda J Andrews; Mark B Gerstein; Michael Snyder; Benjamin E Turk
Deciphering protein kinase specificity through large-scale analysis of yeast phosphorylation site motifs.
Science signaling 2010;3(109):ra12.
2009: S Agarwal; Cynthia A Zerillo; J Kolmakova; J G Christensen; Lyndsay N Harris; David L Rimm; Michael P DiGiovanna; David F Stern
Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells.
British journal of cancer 2009;100(6):941-9.
2009: David F Stern
BRCTing up is hard to do.
Molecular cell 2009;33(2):137-8.
2008: Kathleen A Wilson; David F Stern
NFBD1/MDC1, 53BP1 and BRCA1 have both redundant and unique roles in the ATM pathway.
Cell cycle (Georgetown, Tex.) 2008;7(22):3584-94.
2008: Christina I Zito; David Riches; Julia Kolmakova; Jan Simons; Michael Egholm; David F Stern
Direct resequencing of the complete ERBB2 coding sequence reveals an absence of activating mutations in ERBB2 amplified breast cancer.
Genes, chromosomes & cancer 2008;47(7):633-8.
2008: David F Stern
ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer.
Journal of mammary gland biology and neoplasia 2008;13(2):215-23.
2008: Michael P DiGiovanna; David F Stern; Susan M Edgerton; Gloria Broadwater; Lynn Dressler; Daniel R Budman; I Craig Henderson; Larry Norton; Edison Liu; Hyman Muss; Donald A Berry; Daniel F Hayes; Ann D Thor
Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(14):2364-72.
2008: Nianhan Jia-Lin Ma; David F Stern
Regulation of the Rad53 protein kinase in signal amplification by oligomer assembly and disassembly.
Cell cycle (Georgetown, Tex.) 2008;7(6):808-17.
2008: Amy J Jackson-Fisher; Gary Bellinger; Jerrica L Breindel; Fatteneh A Tavassoli; Carmen J Booth; James K Duong; David F Stern
ErbB3 is required for ductal morphogenesis in the mouse mammary gland.
Breast cancer research : BCR 2008;10(6):R96.
2006: Amy J Jackson-Fisher; G Bellinger; E Shum; Jimmy K Duong; Archibald S Perkins; M Gassmann; W Muller; K C Kent Lloyd; David F Stern
Formation of Neu/ErbB2-induced mammary tumors is unaffected by loss of ErbB4.
Oncogene 2006;25(41):5664-72.
2006: Jia-Lin Ma; Soo-Jung Lee; Jimmy K Duong; David F Stern
Activation of the checkpoint kinase Rad53 by the phosphatidyl inositol kinase-like kinase Mec1.
The Journal of biological chemistry 2006;281(7):3954-63.
2005: Jason Ptacek; Geeta Devgan; Gregory A Michaud; Heng Zhu; Xiaowei Zhu; Joseph Fasolo; Hong Guo; Ghil Jona; Ashton Breitkreutz; Richelle Sopko; Rhonda R McCartney; Martin C Schmidt; Najma Rachidi; Soo-Jung Lee; Angie S Mah; Lihao Meng; Michael J R Stark; David F Stern; Claudio de Virgilio; Mike Tyers; Brenda Andrews; Mark Gerstein; Barry Schweitzer; Paul Predki; Michael Snyder
Global analysis of protein phosphorylation in yeast.
Nature 2005;438(7068):679-84.
2005: Jia Li; C S H Young; Paul Lizardi; David F Stern
In situ detection of specific DNA double strand breaks using rolling circle amplification.
Cell cycle (Georgetown, Tex.) 2005;4(12):1767-73.
2005: Jia Li; David F Stern
DNA damage regulates Chk2 association with chromatin.
The Journal of biological chemistry 2005;280(45):37948-56.
2005: Dhara N Amin; David Tuck; David F Stern
Neuregulin-regulated gene expression in mammary carcinoma cells.
Experimental cell research 2005;309(1):12-23.
2005: David F Stern
Phosphoproteomics for oncology discovery and treatment.
Expert opinion on therapeutic targets 2005;9(4):851-60.
2005: Lyuben Tsvetkov; Rumiana T Tsekova; Xingzhi Xu; David F Stern
The Plk1 Polo box domain mediates a cell cycle and DNA damage regulated interaction with Chk2.
Cell cycle (Georgetown, Tex.) 2005;4(4):609-17.
2005: Jia Li; David F Stern
Regulation of CHK2 by DNA-dependent protein kinase.
The Journal of biological chemistry 2005;280(12):12041-50.
2005: Lyuben Tsvetkov; David F Stern
Interaction of chromatin-associated Plk1 and Mcm7.
The Journal of biological chemistry 2005;280(12):11943-7.
2005: Michael P DiGiovanna; David F Stern; Susan M Edgerton; Steve G Whalen; Dan Moore; Ann D Thor
Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(6):1152-60.
2005: Shanu Modi; Michael P DiGiovanna; Zhao Lu; Chaya S Moskowitz; Katherine S Panageas; Catherine Van Poznak; Clifford Hudis; Larry Norton; Lee Tan; David F Stern; Darryl L Carter; Andrew D Seidman
Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer.
Cancer investigation 2005;23(6):483-7.
2005: Lyuben Tsvetkov; David F Stern
Phosphorylation of Plk1 at S137 and T210 is inhibited in response to DNA damage.
Cell cycle (Georgetown, Tex.) 2005;4(1):166-71.
2004: Amy J Jackson-Fisher; Gary Bellinger; Rajani Ramabhadran; Jacqueline K Morris; Kuo-Fen Lee; David F Stern
ErbB2 is required for ductal morphogenesis of the mammary gland.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(49):17138-43.
2004: Soo-Jung Lee; Jimmy K Duong; David F Stern
A Ddc2-Rad53 fusion protein can bypass the requirements for RAD9 and MRC1 in Rad53 activation.
Molecular biology of the cell 2004;15(12):5443-55.
2004: David F Stern
More than a marker... Phosphorylated Akt in prostate carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(19):6407-10.
2004: Xingzhi Xu; Juhie Lee; David F Stern
Microcephalin is a DNA damage response protein involved in regulation of CHK1 and BRCA1.
The Journal of biological chemistry 2004;279(33):34091-4.
2004: Dhara N Amin; Archibald S Perkins; David F Stern
Gene expression profiling of ErbB receptor and ligand-dependent transcription.
Oncogene 2004;23(7):1428-38.
2003: Xingzhi Xu; David F Stern
NFBD1/MDC1 regulates ionizing radiation-induced focus formation by DNA checkpoint signaling and repair factors.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2003;17(13):1842-8.
2003: Soo-Jung Lee; Marc F Schwartz; Jimmy K Duong; David F Stern
Rad53 phosphorylation site clusters are important for Rad53 regulation and signaling.
Molecular and cellular biology 2003;23(17):6300-14.
2003: Marc F Schwartz; Soo-Jung Lee; Jimmy K Duong; Seda Eminaga; David F Stern
FHA domain-mediated DNA checkpoint regulation of Rad53.
Cell cycle (Georgetown, Tex.) 2003;2(4):384-96.
2003: David F Stern
ErbBs in mammary development.
Experimental cell research 2003;284(1):89-98.
2003: Xingzhi Xu; David F Stern
NFBD1/KIAA0170 is a chromatin-associated protein involved in DNA damage signaling pathways.
The Journal of biological chemistry 2003;278(10):8795-803.
2003: Lyuben Tsvetkov; Xingzhi Xu; Jia Li; David F Stern
Polo-like kinase 1 and Chk2 interact and co-localize to centrosomes and the midbody.
The Journal of biological chemistry 2003;278(10):8468-75.
2002: Michael P DiGiovanna; Peiguo Chu; Tracey L Davison; Christine L Howe; Darryl L Carter; Elizabeth B Claus; David F Stern
Active signaling by HER-2/neu in a subpopulation of HER-2/neu-overexpressing ductal carcinoma in situ: clinicopathological correlates.
Cancer research 2002;62(22):6667-73.
2002: Michael P DiGiovanna; David F Stern; Robert R Roussel
Production of antibodies that recognize specific tyrosine-phosphorylated peptides.
Current protocols in immunology / edited by John E. Coligan ... [et al.] 2002;Chapter 11():Unit 11.6.
2002: Xingzhi Xu; Lyuben Tsvetkov; David F Stern
Chk2 activation and phosphorylation-dependent oligomerization.
Molecular and cellular biology 2002;22(12):4419-32.
2002: Marc F Schwartz; Jimmy K Duong; Zhaoxia Sun; Jon S Morrow; Deepti Pradhan; David F Stern
Rad9 phosphorylation sites couple Rad53 to the Saccharomyces cerevisiae DNA damage checkpoint.
Molecular cell 2002;9(5):1055-65.
2002: Michael P DiGiovanna; Robert R Roussel; David F Stern
Production of antibodies that recognize specific tyrosine-phosphorylated peptides.
Current protocols in cell biology / editorial board, Juan S. Bonifacino ... [et al.] 2002;Chapter 16():Unit 16.6.
2001: David F Stern
HER-2 testing in prostate carcinoma.
Cancer journal (Sudbury, Mass.) 2001;7(5):372-4.
2001: David F Stern
Phosphoproteomics.
Experimental and molecular pathology 2001;70(3):327-31.
2001: Elizabeth B Claus; Peiguo Chu; Christine L Howe; T L Davison; David F Stern; Darryl L Carter; Michael P DiGiovanna
Pathobiologic findings in DCIS of the breast: morphologic features, angiogenesis, HER-2/neu and hormone receptors.
Experimental and molecular pathology 2001;70(3):303-16.
2001: Michael P DiGiovanna; R R Roussel; David F Stern
Production of antibodies that recognize specific tyrosine-phosphorylated peptides.
Current protocols in molecular biology / edited by Frederick M. Ausubel ... [et al.] 2001;Chapter 18():Unit 18.6.
2000: Ann D Thor; S Liu; Susan M Edgerton; D Moore; K M Kasowitz; Christopher C Benz; David F Stern; Michael P DiGiovanna
Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(18):3230-9.
2000: David F Stern
Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases.
Breast cancer research : BCR 2000;2(3):176-83.
1999: F E Jones; T Welte; Xin-Yuan Fu; David F Stern
ErbB4 signaling in the mammary gland is required for lobuloalveolar development and Stat5 activation during lactation.
The Journal of cell biology 1999;147(1):77-88.
1999: F E Jones; David F Stern
Expression of dominant-negative ErbB2 in the mammary gland of transgenic mice reveals a role in lobuloalveolar development and lactation.
Oncogene 1999;18(23):3481-90.
1998: Michael P DiGiovanna; M A Lerman; R J Coffey; W J Muller; Robert Cardiff; David F Stern
Active signaling by Neu in transgenic mice.
Oncogene 1998;17(14):1877-84.
1998: Christine Burke; David F Stern
Activation of Neu (ErbB-2) mediated by disulfide bond-induced dimerization reveals a receptor tyrosine kinase dimer interface.
Molecular and cellular biology 1998;18(9):5371-9.
1998: Zhaoxia Sun; J Hsiao; David Fay; David F Stern
Rad53 FHA domain associated with phosphorylated Rad9 in the DNA damage checkpoint.
Science (New York, N.Y.) 1998;281(5374):272-4.
1998: DJ Riese; T Komurasaki; Greg Plowman; David F Stern
Activation of ErbB4 by the bifunctional epidermal growth factor family hormone epiregulin is regulated by ErbB2.
The Journal of biological chemistry 1998;273(18):11288-94.
1998: DJ Riese; David F Stern
Specificity within the EGF family/ErbB receptor family signaling network.
BioEssays : news and reviews in molecular, cellular and developmental biology 1998;20(1):41-8.
1997: H Chang; DJ Riese; Walter Gilbert; David F Stern; Uel J McMahan
Ligands for ErbB-family receptors encoded by a neuregulin-like gene.
Nature 1997;387(6632):509-12.
1997: Christine Burke; M A Lemmon; B A Coren; Donald M Engelman; David F Stern
Dimerization of the p185neu transmembrane domain is necessary but not sufficient for transformation.
Oncogene 1997;14(6):687-96.
1997: S Kannan; ML De Santis; M Lohmeyer; DJ Riese; Gilbert H Smith; N Hynes; Masaharu Seno; R Brandt; Caterina Bianco; G Persico; Nicholas Kenney; Nicola Normanno; I Martinez-Lacaci; F Ciardiello; David F Stern; W J Gullick; David S Salomon
Cripto enhances the tyrosine phosphorylation of Shc and activates mitogen-activated protein kinase (MAPK) in mammary epithelial cells.
The Journal of biological chemistry 1997;272(6):3330-5.
1997: David Fay; Zhaoxia Sun; David F Stern
Mutations in SPK1/RAD53 that specifically abolish checkpoint but not growth-related functions.
Current genetics 1997;31(2):97-105.
1996: Guillermo García-Cardeña; R Fan; David F Stern; J Liu; William C Sessa
Endothelial nitric oxide synthase is regulated by tyrosine phosphorylation and interacts with caveolin-1.
The Journal of biological chemistry 1996;271(44):27237-40.
1996: Michael P DiGiovanna; Darryl L Carter; Stuart D Flynn; David F Stern
Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours.
British journal of cancer 1996;74(5):802-6.
1996: DJ Riese; E D Kim; Klaus Elenius; S Buckley; Michael Klagsbrun; Greg Plowman; David F Stern
The epidermal growth factor receptor couples transforming growth factor-alpha, heparin-binding epidermal growth factor-like factor, and amphiregulin to Neu, ErbB-3, and ErbB-4.
The Journal of biological chemistry 1996;271(33):20047-52.
1996: F E Jones; D J Jerry; B C Guarino; glenn andrews; David F Stern
Heregulin induces in vivo proliferation and differentiation of mammary epithelium into secretory lobuloalveoli.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1996;7(8):1031-8.
1996: Zhaoxia Sun; David Fay; Federica Marini; Marco Foiani; David F Stern
Spk1/Rad53 is regulated by Mec1-dependent protein phosphorylation in DNA replication and damage checkpoint pathways.
Genes & development 1996;10(4):395-406.
1996: DJ Riese; Y Bermingham; T M van Raaij; S Buckley; Greg Plowman; David F Stern
Betacellulin activates the epidermal growth factor receptor and erbB-4, and induces cellular response patterns distinct from those stimulated by epidermal growth factor or neuregulin-beta.
Oncogene 1996;12(2):345-53.
1995: DJ Riese; T M van Raaij; Greg Plowman; glenn andrews; David F Stern
The cellular response to neuregulins is governed by complex interactions of the erbB receptor family.
Molecular and cellular biology 1995;15(10):5770-6.
1995: Michael P DiGiovanna; David F Stern
Activation state-specific monoclonal antibody detects tyrosine phosphorylated p185neu/erbB-2 in a subset of human breast tumors overexpressing this receptor.
Cancer research 1995;55(9):1946-55.
1993: Pan Zheng; David Fay; J Burton; H Xiao; J L Pinkham; David F Stern
SPK1 is an essential S-phase-specific gene of Saccharomyces cerevisiae that encodes a nuclear serine/threonine/tyrosine kinase.
Molecular and cellular biology 1993;13(9):5829-42.
1992: L Bangalore; A J Tanner; A P Laudano; David F Stern
Antiserum raised against a synthetic phosphotyrosine-containing peptide selectively recognizes p185neu/erbB-2 and the epidermal growth factor receptor.
Proceedings of the National Academy of Sciences of the United States of America 1992;89(23):11637-41.
1992: H Cao; L Bangalore; C Dompé; B J Bormann; David F Stern
An extra cysteine proximal to the transmembrane domain induces differential cross-linking of p185neu and p185neu.
The Journal of biological chemistry 1992;267(28):20489-92.
1992: H Cao; L Bangalore; B J Bormann; David F Stern
A subdomain in the transmembrane domain is necessary for p185neu* activation.
The EMBO journal 1992;11(3):923-32.
1991: Y Dobashi; David F Stern
Membrane-anchored forms of EGF stimulate focus formation and intercellular communication.
Oncogene 1991;6(7):1151-9.
1991: H Cao; S Decker; David F Stern
TPA inhibits the tyrosine kinase activity of the neu protein in vivo and in vitro.
Oncogene 1991;6(5):705-11.
1991: David F Stern; Pan Zheng; D R Beidler; C Zerillo
Spk1, a new kinase from Saccharomyces cerevisiae, phosphorylates proteins on serine, threonine, and tyrosine.
Molecular and cellular biology 1991;11(2):987-1001.
1990: P A Connelly; David F Stern
The epidermal growth factor receptor and the product of the neu protooncogene are members of a receptor tyrosine phosphorylation cascade.
Proceedings of the National Academy of Sciences of the United States of America 1990;87(16):6054-7.
1990: E Filvaroff; David F Stern; G Paolo Dotto
Tyrosine phosphorylation is an early and specific event involved in primary keratinocyte differentiation.
Molecular and cellular biology 1990;10(3):1164-73.
1988: David F Stern; M P Kamps; H Cao
Oncogenic activation of p185neu stimulates tyrosine phosphorylation in vivo.
Molecular and cellular biology 1988;8(9):3969-73.
1988: David F Stern; M P Kamps
EGF-stimulated tyrosine phosphorylation of p185neu: a potential model for receptor interactions.
The EMBO journal 1988;7(4):995-1001.